Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2011-05-17
2011-05-17
Parkin, Jeffrey S (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
Reexamination Certificate
active
07943146
ABSTRACT:
The present invention provides methods for preventing and treating HIV infection and AIDS by introducing cells displaying HIV late-domain phenotype into a patient, or by administering to a patient nucleic acids, polypeptides or small organic compounds to cause the formation of cells displaying HIV late-domain phenotype in the body of the patient.
REFERENCES:
patent: 5443828 (1995-08-01), Kang et al.
patent: 5807995 (1998-09-01), Cohen et al.
patent: 5891668 (1999-04-01), Li et al.
patent: 5892016 (1999-04-01), Brie et al.
patent: 5965726 (1999-10-01), Pavlakis et al.
patent: 6099847 (2000-08-01), Tobin et al.
patent: 6248523 (2001-06-01), Cohen et al.
patent: 6274312 (2001-08-01), Gish et al.
patent: 6291227 (2001-09-01), Haynes et al.
patent: 6348449 (2002-02-01), Weiner et al.
patent: WO 02/072790 (2002-09-01), None
patent: WO 02/094314 (2002-11-01), None
patent: WO 03/015708 (2003-02-01), None
patent: WO 03/053332 (2003-07-01), None
Garrus, J. E., et al., 2001, Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding, Cell 107:55-65.
Wyma, D. J., et al., 2000, Evidence for a stable interaction of gp41 with Pr55Gag in immature human immunodeficiency virus type 1 particles, J. Virol. 74(20):9381-9387.
2008, Instructions to authors, J. Virol. 82:1):1-19.
Garnier, L., et al., 1998, Particle size determinants in the human immunodeficiency virus type 1 Gag protein, J. Virol. 72(6):4667-4677.
Barouch, D. H., et al., 2000, Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination, Science 290:486-492.
Farrar, Graham H., et al., “Characterisation of a Series of Human Immunodeficiency Virus Isolates Derived Sequentially From a Single Patient”,Journal of Medical Virology, 1991; 34:104-113.
Schwartz, Stefan, et al., “Mutational Inactivation of an Inhibitory Sequence in Human Immunodeficiency Virus Type 1 Results in Rev-IndependentgagExpression”,Journal of Virology, Dec. 1992; 66(12):7176-7182.
Fynan, Ellen F., et al., “DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations”,Proc. Natl. Acad. Sci. USA, Dec. 1993; 90:11478-11482.
Whittle, Peter J., “Protein Structure-Based Drug Design”,Annu. Rev. Biophys. Biomol. Struct., 1994; 23:34-375.
Mhashilkar, Abner, et al., “Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies”,The EMBO Journal, 1995; 14(7):1542-1551.
U.S. Appl. No. 09/971,549, filed Oct. 4, 2001, Zavitz et al.
U.S. Appl. No. 09/972,035, filed Nov. 21, 2002, Wettstein et al.
U.S. Appl. No. 10/098,979, filed Nov. 28, 2002, Sugiyama et al.
U.S. Appl. No. 10/097,534, filed Mar. 13, 2003, Greener et al.
U.S. Appl. No. 10/223,172, filed Jul. 24, 2003, Zavitz et al.
U.S. Appl. No. 10/224,999, filed Sep. 11, 2003, Morham et al.
U.S. Appl. No. 10/663,407, filed Sep. 15, 2003, Zavitz et al.
Parent, Leslie J., et al., “Positionally Independent and Exchangeable Late Budding Functions of the Rous Sarcoma Virus and Human Immunodeficiency Virus Gag Proteins”,Journal of Virology, Sep. 1995; 69(9):5455-5460.
Huang, Mingjun, et al., “p6GAGIs Required for Particle Production from Full-Length Human Immunodeficiency Virus Type 1 Molecular Clones Expressing Protease”,Journal of Virology, Nov. 1995; 69(11):6810-6818.
NCBI Entrez Protein Database Accession No. AAB38034, Dec. 5, 1996.
Rossi, John J., Therapeutic applications of catalytic Antisense RNAs (ribozymes),CIBA Foundation Symposium, 1997; 209:195-204.
Levin, Rueven, et al., “Inhibition of Early and Late Events of the HIV-1 Replication Cycle by Cytoplasmic Fab Intrabodies against the Matrix Protein, p17”,Molecular Medicine, Feb. 1997; 3(2):96-110.
Roman, Mark, et al., “Immunostimulatory DNA sequences function as T helper-1- promoting adjuvants”,Nature Medicine, Aug. 1997; 3(8):849.
Burton, Dennis R., “A vaccine for HIV type 1: The antibody perspective”,Proc. Natl. Acad. Sci. USA, Sep. 1997; 94:10018-10023.
Puffer, Bridget A., et al., “Equine Infectious Anemia Virus Utilizes a YXXL Motif within the Late Assembly Domain of the Gag p9 Protein”,Journal of Virology, Sep. 1997; 71(9):6541-6546.
Zhang, Yi-Ming, et al., “Drug Resistance during Indinavir Therapy Is Caused by Mutations in the Protease Gene and in Its Gag Substrate Cleavage Sites,Journal of Virology”, Sep. 1997; 71(9):6662-6670.
NCBI Entrez Protein Database Accession No. AAB83138, Nov. 6, 1997.
NCBI Entrez Protein Database Accession No. AAB83216, Nov. 6, 1997.
NCBI Entrez Protein Database Accession No. AAB83821, Nov. 6, 1997.
Savarino, Andrea, et al., “The Biochemistry of Gene Therapy for AIDS”,Clin. Chem. Lab. Med., 1998; 36(4):205-210.
Zhang, Yaqiang, et al., “Analysis of the Assembly Function of the Human Immunodeficiency Virus Type 1 Gag Protein Nucleocapsid Domain”,Journal of Virology, Mar. 1998: 72(3):1782-1789.
Yasuda, Jiro, et al., “A Proline-Rich Motif (PPPY) in the Gag Polyprotein of Mason-Pfizer Monkey Virus Plays a Maturation-Independent Role in Virion Release”,Journal of Virology, May 1998; 72(5):4095-4103.
Letvin, Norman L., “Progress in the Development of an HIV-1 Vaccine”,Science, Jun. 19, 1998: 280:1875-1880.
NCBI Entrez Protein Database Accession No. P35962, Jul. 15, 1998.
Crump, Colin M., et al., “Inhibition of the Interaction between Tyrosine-based Motifs and the Medium Chain Subunit of the AP-2 Adaptor Complex by Specific Tyrphostins”,The Journal of Biological Chemistry, Oct. 23, 1998; 273(43):28073-28077.
Borsetti, Alessandra, et al., “The C-Terminal Half of the Human Immunodeficiency Virus Type 1 Gag Precursor Is Sufficient for Efficient Particle Assembly”,Journal of Virology, Nov. 1998: 72(11):9313-9317.
Dubensky, Thomas W., et al., “Live virus vaccines: Something old, something new, something borrowed . . . ”,Nature Medicine, Dec. 1998; 4(12):1357-1358.
Puffer, Bridget A., et al., “Equine Infectious Anemia Virus Gag Polyprotein Late Domain Specifically Recruits Cellular AP-2 Adapter Protein Complexes during Virion Assembly”,Journal of Virology, Dec. 1998; 72(12):10218-10221.
Sorkina, Tatiana, et al., “Clathrin, adaptors and eps15 in endosomes containing activated epidermal growth factor receptors”,Journal of Cell Science, 1999: 112:317-327.
Verkhivker, Gennady M., et al., “Towards understanding the mechanisms of molecular recognition by computer simulations of ligand-protein interactions”,Journal of Molecular Recognition, 1999; 12:371-389.
Yuan, Bing, et al., “Mutations altering the Moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle”,The EMBO Journal, 1999; 18(17):4700-4710.
NCBI Entrez Protein Database Accession No. AAD03232, Jan. 6, 1999.
NCBI Entrez Protein Database Accession No. AAD03240, Jan. 6, 1999.
Garnier, Laurence, et al., “Identification of Retroviral Late Domains as Determinants of Particle Size”,Journal of Virology, Mar. 1999; 73(3):2309-2320.
Craven, Rebecca C. et al., “Late Domain Function Identified in the Vesicular Stomatitis Virus M Protein by Use of Rhabdovirus-Retrovirus Chimeras”,Journal of Virology, Apr. 1999; 73(4):3359-3365.
Harty, Ronald N., et al., “A Proline-Rich Motif within the Matrix Protein of Vesicular Stomatitis Virus and Rabies Virus Interacts with WW Domains of Cellular Proteins: Implications for Viral Budding”,Journal of Virology, Apr. 1999; 73(4):2921-2929.
Harvey, Kieran F., et al., “Nedd4-like proteins: an emerging family of ubiquitin-protein ligases implicated in diverse cellular functions”,Trends in Cell Biology, May 1999: 9;166-169.
Li, Yu, et al., “Yeast Mutants Affecting Possible Quality Control of Plasma Membrane Proteins”,Molecular and Cellular Biology, May 1999; 19(5):3588-3599.
Deschambeault, Julie, et al., ȁ
Hobden Adrian
Morham Scott
Zavitz Kenton
Echols Kelly A.
Ley, III Herbert L.
Myrexis IP Group
Myrexis, Inc.
Parkin Jeffrey S
LandOfFree
Immunizing compositions comprising HIV-1 proviral constructs... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunizing compositions comprising HIV-1 proviral constructs..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunizing compositions comprising HIV-1 proviral constructs... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2683088